Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) — Oct 14th, 2024

PASADENA, Calif., October 14, 2024--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 11, 2024, the Company’s Board of Directors approved "inducement" grants to 34 new employees u...

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) — Oct 14th, 2024

PASADENA, Calif., October 14, 2024--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 11, 2024, the Company’s Board of Directors approved "inducement" grants to 34 new employees u...

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) — Oct 14th, 2024

PASADENA, Calif., October 14, 2024--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 11, 2024, the Company’s Board of Directors approved "inducement" grants to 34 new employees u...

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) — Oct 14th, 2024

PASADENA, Calif., October 14, 2024--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 11, 2024, the Company’s Board of Directors approved "inducement" grants to 34 new employees u...

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) — Oct 14th, 2024

PASADENA, Calif., October 14, 2024--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 11, 2024, the Company’s Board of Directors approved "inducement" grants to 34 new employees u...

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) — Oct 14th, 2024

PASADENA, Calif., October 14, 2024--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 11, 2024, the Company’s Board of Directors approved "inducement" grants to 34 new employees u...

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity — Sep 23rd, 2024

- In preclinical studies ARO-INHBE reduced body weight and fat mass with a novel mechanism of action that may preserve lean muscle mass compared to currently approved obesity therapies PASADENA, Calif., September 23, 2024--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) to...

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) — Oct 14th, 2024

PASADENA, Calif., October 14, 2024--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 11, 2024, the Company’s Board of Directors approved "inducement" grants to 34 new employees u...

With 73% ownership of the shares, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is heavily dominated by institutional owners — Sep 23rd, 2024

Key Insights Given the large stake in the stock by institutions, Arrowhead Pharmaceuticals' stock price might be vulnerable to their trading decisions A total of 9 investors have a majority stake in the company with 51% ownership Ownership research along with analyst forecasts data help...

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) — Oct 14th, 2024

PASADENA, Calif., October 14, 2024--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 11, 2024, the Company’s Board of Directors approved "inducement" grants to 34 new employees u...